A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study

Elife. 2020 Nov 26:9:e63195. doi: 10.7554/eLife.63195.

Abstract

COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.

Keywords: COVID-19; complete blood count; haemocytometry; human; intensive care; medicine; prognostic score.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Cell Count / instrumentation
  • Blood Cell Count / methods
  • Blood Cell Count / statistics & numerical data*
  • COVID-19 / blood*
  • COVID-19 / epidemiology
  • COVID-19 / virology
  • Cohort Studies
  • Europe
  • Female
  • Hospitalization / statistics & numerical data*
  • Hospitals*
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Prognosis
  • Retrospective Studies
  • SARS-CoV-2 / physiology
  • Young Adult

Grants and funding

Sysmex Europe GMBH provided free of charge reagents for the study. No monetary payments were made to any of the investigators. Joachim Linssen, Jarob Saker and Marion Münster are full-time employees of Sysmex Europe GMBH and Andre van der Ven has an ad hoc consultancy agreement with Sysmex Europe GMBH.